Immunoblot analyses validated interactions of analog 19 with key BCR (BTK) and NFκB (p65, IKKβ, IKKα, RELB) pathway proteins (Fig. 3E), indicating SpiD3 affects key CLL survival pathways and disrupts both canonical and noncanonical NFκB signaling. Here, RELB is linked to B-cell chronic lymphocytic leukemia.